An interventional study of Behavioural Experimental: guidelines-based physical activity and Behavioural Experimental: guidelines-based physical activity and healthy eating in Metabolic Disturbance and Sedentary Behavior, sponsored by University of Toronto. Recruiting at 1 site in Canada. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by University of Toronto · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Sedentary Behavior with a site in Canada — 18 open to participants now, 19 under way, none of them phase 3. Sedentary Behavior · Canada.
Among the 73 studies in Sedentary Behavior with a site in Canada, this one is the 15th largest by planned enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2024, is one of 67 with no phase, reaches primary completion later than 14 of the 18 other live ones, and was the 61st registered.
1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.
Browse Sedentary Behavior studies →18 of the 73 studies in Sedentary Behavior with a site in Canada are open now. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 50+
University of Alberta · Sites in Canada
Ages 50+
The Royal Ottawa Mental Health Centre · Sites in Canada
Ages 18–75
Nova Scotia Health Authority · Sites in Canada
Ages 65+
Université de Sherbrooke · Sites in Canada
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.
This study: 30 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 1,077 interventional studies indexed under Sedentary Behavior.
Median enrollment 50 across the 69 interventional studies, 336 across the 4 observational. Of the 46 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 73 has an industry lead sponsor. The 10 most frequent:
University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.
University of Toronto has 9 studies filed under Sedentary Behavior — fewer than ten, so there is no comparison to draw.
5 of the studies in Sedentary Behavior with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07396857Université de SherbrookeThe Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting | 2026-12-15 |
| NCT06773949The Royal Ottawa Mental Health CentreFeasibility Trial of Exercise as a Priming Strategy for rTMS Treatment in Difficult-to-Treat Depression | 2027-01-31 |
| NCT06252259University of British ColumbiaEvaluating Implementation and Impact of the Adapted Choose to Move (CTM) Program | 2027-03 |
| NCT06446414University of British ColumbiaEvaluating Implementation and Impact of Provincial Scale-up of the Adapted Choose to Move (CTM) Program | 2027-04 |
| NCT06345937University of TorontoMultiple Risk Factor Intervention Trial (Ms. FIT) | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 73 studies in Sedentary Behavior with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Using a 3-arm randomized controlled trial (RCT) with equal recruitment and stratification by menopausal status to 6 months of: 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions:
The investigators hypothesize that exercise adaptations will be: 1) largest peripherally, including Matsuda index (primary outcome), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), arteriovenous oxygen difference (avO2diff), and visceral fat, compared to centrally (stroke volume (SV), endothelial function, aortic stiffness), 2) blunted or absent in post vs premenopause; 3) enhanced by the addition of diet quality which will be essential or additive for Matsuda index, metabolic syndrome, Framingham cardiovascular disease (CVD) risk, cytokines and adipokines, thigh myosteatosis, muscle mass, peak oxygen uptake (VO2peak), 4) enhanced by adding diet quality in more outcomes postmenopause.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
Behavioral: Behavioural Experimental: guidelines-based physical activity
150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
Behavioral: Behavioural Experimental: guidelines-based physical activity and healthy eating
Whole-body stretching
Behavioral: Behavioural: Stretching exercise
Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
Behavioural Experimental: guidelines-based physical activity: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening. Behavioural Experimental: guidelines-based healthy eating: One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
Twice weekly virtual instructor-led whole-body stretching.
Insulin resistance
As assessed by the Matsuda Index calculated from an oral glucose tolerance test (OGTT).
Time frame: 6 months
Hepatic insulin resistance
Indirectly measured via HOMA-IR using fasting glucose and insulin levels
Time frame: 6 months
Metabolic syndrome severity
Calculated as a z-score to allow for tracking change in the interventions
Time frame: 6 months
Framingham 10-year risk (%)
Calculated using a widely-used standardized scoring system
Time frame: 6 months
Cardiorespiratory fitness
Measured as peak volume of oxygen consumption via indirect calorimetry during a cardiopulmonary exercise test on a treadmill.
Time frame: 6 months
Heart Rate Recovery
Measured as the difference between peak heart rate during the cardiorespiratory fitness test and heart rate 2-minutes after stopping the exercise test.
Time frame: 6 months
Exercise stroke volume & cardiac output
Measured during submaximal and maximal periods of a cycling exercise test, using echocardiography.
Time frame: 6 months
Left ventricular ejection fraction
Measured during rest, submaximal and maximal periods of cycling exercise test, using echocardiography
Time frame: 6 months
Left ventricular mass
Measured via echocardiography at rest
Time frame: 6 months
Arteriovenous Oxygen Difference (avO2diff)
Measured using two methods: (1) calculated as the volume of oxygen (VO2) from the corresponding workload from the day 1 treadmill test divided by cardiac output at rest, submaximal, and maximal periods of the cycling exercise test; and (2) direct assessment using near-infrared spectroscopy as a measure of tissue oxygenation in the legs at rest, submaximal, and maximal periods of the cycling exercise test.
Time frame: 6 months
Endothelial Function
Measured using a brachial artery flow-mediated dilation test using ultrasound.
Time frame: 6 months
Carotid Intima Media Thickness
Measured using a common carotid artery image using ultrasound.
Time frame: 6 months
Central & Peripheral Arterial stiffness
Measured as the pulse wave velocity of the central (carotid-femoral) and peripheral leg (femoral-dorsalis pedis) and arm (carotid-radial) regions. Blood pressure may be added as covariate in analysis of arterial stiffness.
Time frame: 6 months
Blood Pressure
Measured as the average of the last 5 of 6 blood pressure measurements using an automatic blood pressure device.
Time frame: 6 months
Resting Heart Rate & Heart Rate Variability
Assessed using a 3-lead electrocardiogram in the supine position for 10 minutes after a 5-minute supine rest.
Time frame: 6 months
Thigh Myosteatosis
Measured as thigh muscle fat fraction (percent of muscle compartment composed of fat pixels) determined from contiguous axial fat-water separation 3 Tesla (3T) magnetic resonance images of both thighs.
Time frame: 6 months
Knee flexion and extension (strength and endurance)
Measured using an isokinetic dynamometer (Biodex) to assess peak torque and total work in 30 repetitions of knee flexion.
Time frame: 6 months
Thigh Muscle Volume
Measured determined from contiguous axial fat-water separation 3T magnetic resonance images of both thighs
Time frame: 6 months
Biochemical markers of skeletal muscle protein content
Measured via western blotting from a skeletal muscle biopsy of the vastus lateralis muscle. Proteins of interest include those found in mitochondria, contractile signaling pathways, insulin signaling pathways, and in glucose and fat metabolism.
Time frame: 6 months
Biochemical markers of skeletal muscle structure
Measured via immunofluorescence from a skeletal muscle biopsy of the vastus lateralis muscle. Outcomes of interest include skeletal muscle capillarization, lipid content, and fiber type and cross sectional area.
Time frame: 6 months
Biochemical markers of skeletal muscle enzyme activity
Measured via spectrophotometer to assess the maximal enzyme activity of enzymes involved in skeletal muscle oxidative capacity, from a biopsy of the vastus lateralis muscle.
Time frame: 6 months
Whole-body fat and fat-free mass
Measured using a body composition device (BodPod) to estimate whole body fat (in kg and %) and fat free mass (in kg and %).
Time frame: 6 months
Visceral adipose tissue
Volumes of adipose tissue in the visceral region measured using 3T fat-water separation magnetic resonance imaging
Time frame: 6 months
Liver fat fraction
Measured as percent of liver volume composed of fat pixels determined from 3 slices through the middle of the liver using the PROFIT1 3T magnetic resonance images sequence.
Time frame: 6 months
Body circumferences
Circumferences of the waist, hip and neck, measured using an inelastic tape
Time frame: 6 months
Concentration of inflammation biomarkers in blood
Assessments from blood including leptin, adiponectin, Tumour Necrosis Factor alpha (TNF-a), Interleukin-6 (IL-6), C-reactive protein (CRP). These measures have been grouped together as the markers will be considered together when interpreted.
Time frame: 6 months
Lipid panel: high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total Cholesterol, Triglycerides
Analyzed from blood serum using a clinical assay at a core lab.
Time frame: 6 months
Hemoglobin A1c
Analyzed from blood plasma using a clinical assay at a core lab.
Time frame: 6 months
Dietary intake
Various components of dietary intake including macronutrients and micronutrients will be assessed through 3-day food records over 2 weekdays and 1 weekend collected using Automated Self-Administered 24hour (ASA-24) online system.
Time frame: 3 months, 6 months, 12 months
Liver enzymes: alanine transaminase (ALT), aspartate aminotransferase (AST), and albumin
Assessment of ALT, AST, and albumin via a fasting blood serum draw, analyzed on a clinical assay at a core lab.
Time frame: 6 months
Liver fibrosis
Liver T1 time evaluated using the PROFIT1 magnetic resonance sequence, validated marker of liver fibrosis.
Time frame: 6 months
Aerobic physical activity adherence
Average adherence to prescribed aerobic physical activity weekly minutes measured via Garmin smart watch
Time frame: 6 months, 12 months
Resistance exercise adherence
Average adherence to prescribed resistance exercise activity weekly sessions via an attendance log
Time frame: 6 months, 12 months
Diet quality
An overall measure of alignment with the dietary guidelines measured via the Canadian healthy eating index calculated from 3-day diet records
Time frame: 3 months, 6 months, 12 months
Health-related quality of life
Assessed by RAND-36, where an independent score is provided for 8 scales ranging from 0 to 100 and 2 component summary scales ranging from 0-50 with a higher score indicating better quality of life.
Time frame: 3 months, 6 months, 12 months
Menopausal symptom presence and severity
Assessed by the Menopause-specific Quality of Life (MENQOL) questionnaire. Each of four domains is constrained between 1 to 8 where a higher score indicates more symptoms.
Time frame: 3 months, 6 months, 12 months
Psychosocial stress
Assessed by the perceived stress scale (PSS-14) where individual scores can range from 0 to 56 with higher scores indicating higher perceived stress
Time frame: 3 months, 6 months, 12 months
Depression & Anxiety
Measured by the Hospital Anxiety and Depression Scale (HADS); score ranges from 0-21 for each of depression and anxiety with a higher score indicating more severe depression or anxiety
Time frame: 3 months, 6 months, 12 months
Barriers and self-efficacy for physical activity
Assessed by the barriers to self-efficacy scale (BARSE). For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100.
Time frame: 3 months, 6 months, 12 months
Physical activity motivation
Assessed via the multi-process action control approach, which is a series of questionnaires developed to understand affective attitudes, instrumental attitudes, perceived capability over physical activity, perceived opportunity for physical activity, decisional intentions, behavioural regulation, physical activity habits, and identity around physical activity. Higher scores represent better physical activity motivations. (Reference: Rhodes, R.E. (2017). The evolving understanding of physical activity behavior: A multi-process action control approach. In A. J. Elliot (Ed), Advances in Motivation Science. (pp. 171-205).)
Time frame: 3 months, 6 months, 12 months
Sleep quality - subjective
Subjectively assessed by the Pittsburgh Sleep Quality Index (PQSI), which measures components of sleep: sleep duration, disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use, with higher scores reflecting poorer sleep quality.
Time frame: 3 months, 6 months, 12 months
Sleep quantity and quality - device measured
Measured via Garmin smart watch for the total sleep duration and efficiency.
Time frame: 3 months, 6 months, 12 months
Self-reported physical activity
Assessed by the Recent Physical Activity Questionnaire (RPAQ) that collects information about types and amounts of activity (sedentary and physical activities) over the last 3 months in the following domains: leisure time, occupation, commuting, domestic life, with greater scores indicating longer time engaging in forms of activity.
Time frame: 3 months, 6 months, 12 months
Serum Estradiol
Assessed using fasting blood serum in a clinical assay.
Time frame: 6 months
Salivary Estradiol
Assessed using a salivary sample in-house using a clinical assay.
Time frame: 6 months
Hemoglobin
Assessed using a fasting blood plasma sample in a clinical assay at a core lab.
Time frame: 6 months
Free fatty acids
Assessed using fasting blood serum in a clinical assay.
Time frame: 6 months
Body weight
Assessed using a calibrated scale attached to the BodPod body composition device.
Time frame: 6 months
Body mass index (BMI)
Calculated from a measurement of height using a stadiometer and body weight (detailed above).
Time frame: 6 months
Energy Balance
Energy balance will be quantified as: 3-day avg calorie intake - \[estimated resting metabolic rate + 3-day avg Garmin estimate of physical activity energy expenditure + 10% of calorie intake (thermic effect of food)\].
Time frame: 3 months, 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.
Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 38 months is above that.
Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.